Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 24 December 1999:
Vol. 286. no. 5449, pp. 2507 - 2510
DOI: 10.1126/science.286.5449.2507
Prev | Table of Contents | Next

Reports

Pharmacological Rescue of Mutant p53 Conformation and Function

Barbara A. Foster, Heather A. Coffey, Michael J. Morin, Farzan Rastinejad *

Compounds that stabilize the DNA binding domain of p53 in the active conformation were identified. These small synthetic molecules not only promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation. A prototype compound caused the accumulation of conformationally active p53 in cells with mutant p53, enabling it to activate transcription and to slow tumor growth in mice. With further work aimed at improving potency, this class of compounds may be developed into anticancer drugs of broad utility.

Department of Genomics, Targets, and Cancer Research, Pfizer Central Research, Eastern Point Road, Groton, CT 06340, USA.
*   To whom correspondence should be addressed. E-mail: Farzan_Rastinejad{at}groton.pfizer.com

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 Rats.
C. V. Rao, V. E. Steele, M. V. Swamy, J. M.R. Patlolla, S. Guruswamy, and L. Kopelovich (2009)
Cancer Res. 69, 8175-8182
   Abstract »    Full Text »    PDF »
Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition.
Z. Wang, M. Zheng, Z. Li, R. Li, L. Jia, X. Xiong, N. Southall, S. Wang, M. Xia, C. P. Austin, et al. (2009)
Cancer Res. 69, 6556-6564
   Abstract »    Full Text »    PDF »
Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1{alpha} and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia.
J. Yang, A. Ahmed, E. Poon, N. Perusinghe, A. de Haven Brandon, G. Box, M. Valenti, S. Eccles, K. Rouschop, B. Wouters, et al. (2009)
Mol. Cell. Biol. 29, 2243-2253
   Abstract »    Full Text »    PDF »
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.
S. Sur, R. Pagliarini, F. Bunz, C. Rago, L. A. Diaz Jr., K. W. Kinzler, B. Vogelstein, and N. Papadopoulos (2009)
PNAS 106, 3964-3969
   Abstract »    Full Text »    PDF »
Identification of ANKRD11 as a p53 coactivator.
P. M. Neilsen, K. M. Cheney, C.-W. Li, J. D. Chen, J. E. Cawrse, R. B. Schulz, J. A. Powell, R. Kumar, and D. F. Callen (2008)
J. Cell Sci. 121, 3541-3552
   Abstract »    Full Text »    PDF »
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling.
E. A. Bassett, W. Wang, F. Rastinejad, and W. S. El-Deiry (2008)
Clin. Cancer Res. 14, 6376-6386
   Abstract »    Full Text »    PDF »
Suppression of Familial Adenomatous Polyposis by CP-31398, a TP53 Modulator, in APCmin/+ Mice.
C. V. Rao, M. V. Swamy, J. M.R. Patlolla, and L. Kopelovich (2008)
Cancer Res. 68, 7670-7675
   Abstract »    Full Text »    PDF »
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.
F. M. Boeckler, A. C. Joerger, G. Jaggi, T. J. Rutherford, D. B. Veprintsev, and A. R. Fersht (2008)
PNAS 105, 10360-10365
   Abstract »    Full Text »    PDF »
iASPP Inhibition: Increased Options in Targeting the p53 Family for Cancer Therapy.
H. S. Bell and K. M. Ryan (2008)
Cancer Res. 68, 4959-4962
   Abstract »    Full Text »    PDF »
Rear-view Mirrors and Crystal Balls: A Brief Reflection on Drug Discovery.
J. S. Lazo (2008)
Mol. Interv. 8, 60-63
   Full Text »    PDF »
CHIP Chaperones Wild Type p53 Tumor Suppressor Protein.
V. Tripathi, A. Ali, R. Bhat, and U. Pati (2007)
J. Biol. Chem. 282, 28441-28454
   Abstract »    Full Text »    PDF »
MDM2 Binding Induces a Conformational Change in p53 That Is Opposed by Heat-shock Protein 90 and Precedes p53 Proteasomal Degradation.
M. Sasaki, L. Nie, and C. G. Maki (2007)
J. Biol. Chem. 282, 14626-14634
   Abstract »    Full Text »    PDF »
Dangerous habits of a security guard: the two faces of p53 as a drug target.
A. V. Gudkov and E. A. Komarova (2007)
Hum. Mol. Genet. 16, R67-R72
   Abstract »    Full Text »    PDF »
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?.
A. A. Levesque and A. Eastman (2007)
Carcinogenesis 28, 13-20
   Abstract »    Full Text »    PDF »
Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification.
A. P. Mitra, R. H. Datar, and R. J. Cote (2006)
J. Clin. Oncol. 24, 5552-5564
   Abstract »    Full Text »    PDF »
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
W. Wang, S.-H. Kim, and W. S. El-Deiry (2006)
PNAS 103, 11003-11008
   Abstract »    Full Text »    PDF »
p53 and breast cancer, an update..
M. Lacroix, R.-A. Toillon, and G. Leclercq (2006)
Endocr. Relat. Cancer 13, 293-325
   Abstract »    Full Text »    PDF »
Early Identification of False Positives in High-Throughput Screening for Activators of p53-DNA Interaction.
J. Wolcke, N. Hunt, J. Jungmann, and D. Ullmann (2006)
J Biomol Screen 11, 341-350
   Abstract »    PDF »
Chemotherapeutic approaches for targeting cell death pathways..
M. S. Ricci and W.-X. Zong (2006)
Oncologist 11, 342-357
   Abstract »    Full Text »    PDF »
Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivo.
F. Talos, O. Petrenko, P. Mena, and U. M. Moll (2005)
Cancer Res. 65, 9971-9981
   Abstract »    Full Text »    PDF »
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs.
V. J. N. Bykov, N. Issaeva, N. Zache, A. Shilov, M. Hultcrantz, J. Bergman, G. Selivanova, and K. G. Wiman (2005)
J. Biol. Chem. 280, 30384-30391
   Abstract »    Full Text »    PDF »
The Ubiquitin-Proteasome Pathway and Its Role in Cancer.
A. Mani and E. P. Gelmann (2005)
J. Clin. Oncol. 23, 4776-4789
   Abstract »    Full Text »    PDF »
Influenza Virus Infection Increases p53 Activity: Role of p53 in Cell Death and Viral Replication.
E. Turpin, K. Luke, J. Jones, T. Tumpey, K. Konan, and S. Schultz-Cherry (2005)
J. Virol. 79, 8802-8811
   Abstract »    Full Text »    PDF »
New Approaches and Therapeutics Targeting Apoptosis in Disease.
U. Fischer and K. Schulze-Osthoff (2005)
Pharmacol. Rev. 57, 187-215
   Abstract »    Full Text »    PDF »
Exploiting the p53 Pathway for the Diagnosis and Therapy of Human Cancer.
D.P. LANE (2005)
Cold Spring Harb Symp Quant Biol 70, 489-497
   Abstract »    PDF »
Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer.
W. Duan, L. Gao, L. J. Druhan, W.-G. Zhu, C. Morrison, G. A. Otterson, and M. A. Villalona-Calero (2004)
J Natl Cancer Inst 96, 1718-1721
   Abstract »    Full Text »    PDF »
Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors.
S. Wuller, B. Wiesner, A. Loffler, J. Furkert, G. Krause, R. Hermosilla, M. Schaefer, R. Schulein, W. Rosenthal, and A. Oksche (2004)
J. Biol. Chem. 279, 47254-47263
   Abstract »    Full Text »    PDF »
CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73.
M. J. Demma, S. Wong, E. Maxwell, and B. Dasmahapatra (2004)
J. Biol. Chem. 279, 45887-45896
   Abstract »    Full Text »    PDF »
The Wilms Tumor Suppressor-1 Target Gene Podocalyxin Is Transcriptionally Repressed by p53.
P. Stanhope-Baker, P. M. Kessler, W. Li, M. L. Agarwal, and B. R. G. Williams (2004)
J. Biol. Chem. 279, 33575-33585
   Abstract »    Full Text »    PDF »
Disorder-associated mutations lead to functional inactivation of neuroligins.
B. Chih, S. K. Afridi, L. Clark, and P. Scheiffele (2004)
Hum. Mol. Genet. 13, 1471-1477
   Abstract »    Full Text »    PDF »
A global suppressor motif for p53 cancer mutants.
T. E. Baroni, T. Wang, H. Qian, L. R. Dearth, L. N. Truong, J. Zeng, A. E. Denes, S. W. Chen, and R. K. Brachmann (2004)
PNAS 101, 4930-4935
   Abstract »    Full Text »    PDF »
Organic Solutes Rescue the Functional Defect in {Delta}F508 Cystic Fibrosis Transmembrane Conductance Regulator.
X.-M. Zhang, X.-T. Wang, H. Yue, S. W. Leung, P. H. Thibodeau, P. J. Thomas, and S. E. Guggino (2003)
J. Biol. Chem. 278, 51232-51242
   Abstract »    Full Text »    PDF »
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.
N. Issaeva, A. Friedler, P. Bozko, K. G. Wiman, A. R. Fersht, and G. Selivanova (2003)
PNAS 100, 13303-13307
   Abstract »    Full Text »    PDF »
Apoptosis - the p53 network.
S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt (2003)
J. Cell Sci. 116, 4077-4085
   Abstract »    Full Text »    PDF »
Macrophage inhibitory cytokine-1: A novel biomarker for p53 pathway activation.
H. Yang, Z. Filipovic, D. Brown, S. N. Breit, and L. T. Vassilev (2003)
Mol. Cancer Ther. 2, 1023-1029
   Abstract »    Full Text »
Sensitization of Pancreatic Tumor Xenografts to Carmustine and Temozolomide by Inactivation of Their O6-Methylguanine-DNA Methyltransferase with O6-Benzylguanine or O6-Benzyl-2'-Deoxyguanosine.
D. M. Kokkinakis, M. M. Ahmed, D. Chendil, R. C. Moschel, and A. E. Pegg (2003)
Clin. Cancer Res. 9, 3801-3807
   Abstract »    Full Text »    PDF »
Reactivation of Mutant p53 by a One-Hybrid Adaptor Protein.
J. Roth, C. Lenz-Bauer, A. Contente, K. Lohr, P. Koch, S. Bernard, and M. Dobbelstein (2003)
Cancer Res. 63, 3904-3908
   Abstract »    Full Text »    PDF »
Kinetic Instability of p53 Core Domain Mutants: IMPLICATIONS FOR RESCUE BY SMALL MOLECULES.
A. Friedler, D. B. Veprintsev, L. O. Hansson, and A. R. Fersht (2003)
J. Biol. Chem. 278, 24108-24112
   Abstract »    Full Text »    PDF »
Why Target Apoptosis in Cancer Treatment?.
S. Kasibhatla and B. Tseng (2003)
Mol. Cancer Ther. 2, 573-580
   Abstract »    Full Text »    PDF »
A Peroxisome Proliferator-activated Receptor-{gamma} Agonist and the p53 Rescue Drug CP-31398 Inhibit the Spontaneous Immortalization of Breast Epithelial Cells.
B.-S. Herbert, V. P. Pearce, L. S. Hynan, D. M. LaRue, W. E. Wright, L. Kopelovich, and J. W. Shay (2003)
Cancer Res. 63, 1914-1919
   Abstract »    Full Text »    PDF »
Pharmacological Chaperone-mediated in Vivo Folding and Stabilization of the P23H-opsin Mutant Associated with Autosomal Dominant Retinitis Pigmentosa.
S. M. Noorwez, V. Kuksa, Y. Imanishi, L. Zhu, S. Filipek, K. Palczewski, and S. Kaushal (2003)
J. Biol. Chem. 278, 14442-14450
   Abstract »    Full Text »    PDF »
Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding.
W. Wang, R. Takimoto, F. Rastinejad, and W. S. El-Deiry (2003)
Mol. Cell. Biol. 23, 2171-2181
   Abstract »    Full Text »    PDF »
Structure-based Design of p18INK4c Proteins with Increased Thermodynamic Stability and Cell Cycle Inhibitory Activity.
R. N. Venkataramani, T. K. MacLachlan, X. Chai, W. S. El-Deiry, and R. Marmorstein (2002)
J. Biol. Chem. 277, 48827-48833
   Abstract »    Full Text »    PDF »
Inactivation of p21WAF1Sensitizes Cells to Apoptosis via an Increase of Both p14ARF and p53 Levels and an Alteration of the Bax/Bcl-2 Ratio.
D. Javelaud and F. Besancon (2002)
J. Biol. Chem. 277, 37949-37954
   Abstract »    Full Text »    PDF »
p53 Moves Into Control of Cell Morphology.
E. Sahai (2002)
Mol. Interv. 2, 286-289
   Abstract »    Full Text »    PDF »
The Conformationally Flexible S9-S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo.
H. Shimizu, L. R. Burch, A. J. Smith, D. Dornan, M. Wallace, K. L. Ball, and T. R. Hupp (2002)
J. Biol. Chem. 277, 28446-28458
   Abstract »    Full Text »    PDF »
Single nucleotide polymorphism seeking long term association with complex disease.
B. W. Kirk, M. Feinsod, R. Favis, R. M. Kliman, and F. Barany (2002)
Nucleic Acids Res. 30, 3295-3311
   Abstract »    Full Text »    PDF »
Mutations in APC, Kirsten-ras, and p53---alternative genetic pathways to colorectal cancer.
G. Smith, F. A. Carey, J. Beattie, M. J. V. Wilkie, T. J. Lightfoot, J. Coxhead, R. C. Garner, R. J. C. Steele, and C. R. Wolf (2002)
PNAS 99, 9433-9438
   Abstract »    Full Text »    PDF »
Apoptosis: Target of Cancer Therapy.
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone (2002)
Clin. Cancer Res. 8, 2024-2034
   Abstract »    Full Text »    PDF »
Tumor Suppressor p53 Mediates Apoptotic Cell Death Triggered by Cyclosporin A.
B. Pyrzynska, M. Serrano, C. Martinez-A., and B. Kaminska (2002)
J. Biol. Chem. 277, 14102-14108
   Abstract »    Full Text »    PDF »
Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Structure-Function Relationships.
M. W. Szkudlinski, V. Fremont, C. Ronin, and B. D. Weintraub (2002)
Physiol Rev 82, 473-502
   Abstract »    Full Text »    PDF »
A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants.
A. Friedler, L. O. Hansson, D. B. Veprintsev, S. M. V. Freund, T. M. Rippin, P. V. Nikolova, M. R. Proctor, S. Rudiger, and A. R. Fersht (2002)
PNAS
   Abstract »    Full Text »    PDF »
UV-induced DNA Damage and Mutations in Hupki (Human p53 Knock-in) Mice Recapitulate p53 Hotspot Alterations in Sun-exposed Human Skin.
J.-L. Luo, W.-M. Tong, J.-H. Yoon, M. Hergenhahn, R. Koomagi, Q. Yang, D. Galendo, G. P. Pfeifer, Z.-Q. Wang, and M. Hollstein (2001)
Cancer Res. 61, 8158-8163
   Abstract »    Full Text »    PDF »
Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism.
W. D. Graf, A. S. Unis, C. M. Yates, S. Sulzbacher, M. B. Dinulos, R. M. Jack, K. A. Dugaw, M. N. Paddock, and W. W. Parson (2001)
Neurology 57, 410-416
   Abstract »    Full Text »    PDF »
Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells.
M. V. Blagosklonny and A. B. Pardee (2001)
Cancer Res. 61, 4301-4305
   Abstract »    Full Text »    PDF »
Tumor Suppressor Protein p53 mRNA and Subcellular Localization Are Altered by Changes in Cellular Copper in Human Hep G2 Cells.
V. S. Narayanan, C. A. Fitch, and C. W. Levenson (2001)
J. Nutr. 131, 1427-1432
   Abstract »    Full Text »
Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.
G. K. Kovvali, B. Mehta, C. B. Epstein, and S. G. Lutzker (2001)
Nucleic Acids Res. 29, e28
   Abstract »    Full Text »    PDF »
Toward Mechanism-Based Cancer Care.
D. M. Livingston and R. Shivdasani (2001)
JAMA 285, 588-593
   Abstract »    Full Text »    PDF »
Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome.
A. Sigal and V. Rotter (2000)
Cancer Res. 60, 6788-6793
   Abstract »    Full Text »
Stabilization and Productive Positioning Roles of the C2 Domain of PTEN Tumor Suppressor.
M.-M. Georgescu, K. H. Kirsch, P. Kaloudis, H. Yang, N. P. Pavletich, and H. Hanafusa (2000)
Cancer Res. 60, 7033-7038
   Abstract »    Full Text »
p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.
M. V. BLAGOSKLONNY (2000)
FASEB J 14, 1901-1907
   Abstract »    Full Text »
p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt (2000)
Carcinogenesis 21, 1441-1451
   Abstract »    Full Text »    PDF »
Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model.
A. Carnero, J. D. Hudson, G. J. Hannon, and D. H. Beach (2000)
Nucleic Acids Res. 28, 2234-2241
   Abstract »    Full Text »    PDF »
Gain-of-Function Mutations in the Tumor Suppressor Gene p53.
M. G. C. T. van Oijen and P. J. Slootweg (2000)
Clin. Cancer Res. 6, 2138-2145
   Abstract »    Full Text »
Drug Discovery: A Historical Perspective.
J. Drews (2000)
Science 287, 1960-1964
   Abstract »    Full Text »
Mechanism-Based Target Identification and Drug Discovery in Cancer Research.
J. B. Gibbs (2000)
Science 287, 1969-1973
   Abstract »    Full Text »
Shoring Up Mutant p53.
(2000)
Journal Watch Dermatology 2000, 10
   Full Text »
The DNA Damage Checkpoint and Human Cancer.
L.B. SCHULTZ, N.H. CHEHAB, A. MALIKZAY, R.A. DITULLIO, E.S. STAVRIDI, and T.D. HALAZONETIS (2000)
Cold Spring Harb Symp Quant Biol 65, 489-498
   Abstract »    PDF »
Crystal Structure of a Conformation-selective Casein Kinase-1 Inhibitor.
N. Mashhoon, A. J. DeMaggio, V. Tereshko, S. C. Bergmeier, M. Egli, M. F. Hoekstra, and J. Kuret (2000)
J. Biol. Chem. 275, 20052-20060
   Abstract »    Full Text »    PDF »
Proper Folding and Endoplasmic Reticulum to Golgi Transport of Tyrosinase Are Induced by Its Substrates, DOPA and Tyrosine.
R. Halaban, E. Cheng, S. Svedine, R. Aron, and D. N. Hebert (2001)
J. Biol. Chem. 276, 11933-11938
   Abstract »    Full Text »    PDF »
High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53.
C. Klein, G. Georges, K.-P. Kunkele, R. Huber, R. A. Engh, and S. Hansen (2001)
J. Biol. Chem. 276, 37390-37401
   Abstract »    Full Text »    PDF »
NMR Spectroscopy Reveals the Solution Dimerization Interface of p53 Core Domains Bound to Their Consensus DNA.
C. Klein, E. Planker, T. Diercks, H. Kessler, K.-P. Kunkele, K. Lang, S. Hansen, and M. Schwaiger (2001)
J. Biol. Chem. 276, 49020-49027
   Abstract »    Full Text »    PDF »
A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants.
A. Friedler, L. O. Hansson, D. B. Veprintsev, S. M. V. Freund, T. M. Rippin, P. V. Nikolova, M. R. Proctor, S. Rudiger, and A. R. Fersht (2002)
PNAS 99, 937-942
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)